The landscape of obesity treatment is undergoing a transformation with the emergence of several novel injectable therapies. the GLP-1/GIP dual agonist, the amylin analogue , a GLP-1/GIP/GCG triple agonist , and https://nexaphresearchpeptides.com/about-us/